Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Natália Da Costa Araújo

    Autor

  • Andreia Filipa Gomes Da Costa

    Autor

  • Maria De Fátima Machado Henriques Carneiro

    Autor

  • Nuno Miguel De Sousa Lunet

    Autor

Participantes de fora da FMUP

  • Lopes-Conceicao, L
  • Ferreira, A
  • Oliveira, J
  • Braga, I
  • Morais, S
  • Pacheco-Figueiredo, L
  • Ruano, L.
  • Cruz, VT
  • Ferreira, S.

Unidades de investigação

Abstract

Background: Androgen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis. Patients and methods: Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes. Results: Mean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, P < 0.001). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, P for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, P for interaction = 0.044). Conclusions: ADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown.

Dados da publicação

ISSN/ISSNe:
2059-7029, 2059-7029

ESMO Open  Elsevier BV

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 3

Citações Recebidas na Scopus: 5

Documentos

  • Não há documentos

Filiações

Filiações não disponíveis

Keywords

  • prostate cancer; neurocognitive disorders; longitudinal studies; hormones; hormone substitutes; hormone antagonists/analogues and derivatives; COVID-19; complications

Proyectos asociados

Quality of Life after Transient Ischemic Attack

Investigador Principal: Andreia Filipa Gomes da Costa

Estudo Clínico Académico (Transient) . 2021

The role of hepatocyte apoptosis markers in predicting the histological and serological activity in steatohepatitis

Investigador Principal: Maria de Fátima Machado Henriques Carneiro

Estudo Clínico Académico . 2021

Healthcare use among cancer patients and their partners in different phases of the cancer pathway

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2021

Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity

Investigador Principal: Maria de Fátima Machado Henriques Carneiro

Estudo Clínico Académico . 2020

RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação